CAPRICOR THERAPEUTICS, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On July 29, 2026, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against the effectiveness of Deramiocel (CAP-1002) for treating cardiomyopathy in DMD patients. The vote was non-binding and addressed a narrower indication than Capricor proposed. However, the Committee gave directionally supportive feedback on upper limb function (skeletal muscle) from the Phase 3 HOPE-3 trial. The FDA PDUFA target action date remains August 22, 2026.
Why this rating
Negative advisory vote on lead indication is material setback for $399M biotech, but non-binding and partial support on skeletal muscle endpoint provides some pathway forward before final FDA decision in 3 weeks.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.